Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

J.P. Morgan sees recent Eli Lilly (LLY) weakness as opportunity ahead of Donanemab Ph3 Data

March 9, 2023 1:01 PM EST

J.P. Morgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE: LLY) ahead of the upcoming release of the donanemab ph3 data.

Analyst Chris Schott wrote in a note, Following recent LLY weakness, we have been receiving a number of questions on the story and wanted to provide our updated thoughts on upcoming donanemab ph3 data as well as... More